Genetic variation in cell death genes and risk of non-hodgkin lymphoma

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Schuetz, Johanna M ^a,b   Daley, Denise ^b   Graham, Jinko ^c   Berry, Brian R ^d   Gallagher, Richard P ^a   Connors, Joseph M ^a   Gascoyne, Randy D ^a   Spinelli, John J ^a,b   Brooks Wilson, Angela R ^a,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d ROYAL JUBILEE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BAX GENE; BBC3 GENE; BCL10 GENE; BCL2 GENE; BCL2L11 GENE; BCL6 GENE; BECN1 GENE; BMI1 GENE; CANCER RISK; CELL DEATH GENE; CONTROLLED STUDY; EUROPE; FAS GENE; FEMALE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MCL1 GENE; MDM2 GENE; MIR155 GENE; MIR15A GENE; NONHODGKIN LYMPHOMA; PMAIP1 GENE; QUALITY CONTROL; RFWD2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SKP2 GENE; CAUCASIAN; CELL DEATH; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; RISK; STATISTICAL MODEL;

MICRORNA;

CELL DEATH; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MICRORNAS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84856703484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031560     Document Type: Article

References (63)

1. Shaffer AL, Rosenwald A, Staudt LM, (2002) Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2: 920-932.
2. Strasser A, (2005) The role of BH3-only proteins in the immune system. Nat Rev Immunol 5: 189-200.
3. Willis TG, Dyer MJ, (2000) The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96: 808-822.
4. Danial NN, (2007) BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 13: 7254-7263.
5. Kelly PN, Strasser A, (2011) The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 18: 1414-1424.
6. Cattoretti G, Shaknovich R, Smith PM, Jack HM, Murty VV, et al. (2006) Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol 177: 6930-6939.
7. Hu S, Du MQ, Park SM, Alcivar A, Qu L, et al. (2006) cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest 116: 174-181.
8. Yue Z, Jin S, Yang C, Levine AJ, Heintz N, (2003) Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 100: 15077-15082.
9. Lessard J, Sauvageau G, (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260.
10. Villa-Morales M, Gonzalez-Gugel E, Shahbazi MN, Santos J, Fernandez-Piqueras J, (2010) Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility. Carcinogenesis 31: 2165-2171.
11. Eischen CM, Alt JR, Wang P, (2004) Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development. Oncogene 23: 8931-8940.
12. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, et al. (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429: 86-92.
13. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, et al. (2001) Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 98: 5043-5048.
14. Aqeilan RI, Calin GA, Croce CM, (2010) miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215-220.
15. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, et al. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414.
16. Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, et al. (2007) microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 27: 847-859.
17. Sipahimalani P, Spinelli JJ, MacArthur AC, Lai A, Leach SR, et al. (2007) A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma. Int J Cancer 121: 1967-1975.
18. Spinelli JJ, Ng CH, Weber JP, Connors JM, Gascoyne RD, et al. (2007) Organochlorines and risk of non-Hodgkin lymphoma. Int J Cancer 121: 2767-2775.
19. Schuetz JM, MaCarthur AC, Leach S, Lai AS, Gallagher RP, et al. (2009) Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. BMC Med Genet 10: 117.
20. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, et al. (2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 41: 508-517.
21. Rozen S, Skaletsky H, (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386.
22. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
23. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, et al. (2005) Efficiency and power in genetic association studies. Nat Genet 37: 1217-1223.
24. Halaschek-Wiener J, Amirabbasi-Beik M, Monfared N, Pieczyk M, Sailer C, et al. (2009) Genetic variation in healthy oldest-old. PLoS One 4: e6641.
25. Halder I, Shriver M, Thomas M, Fernandez JR, Frudakis T, (2008) A panel of ancestry informative markers for estimating individual biogeographical ancestry and admixture from four continents: utility and applications. Hum Mutat 29: 648-658.
26. Mead S, Poulter M, Beck J, Uphill J, Jones C, et al. (2008) Successful amplification of degraded DNA for use with high-throughput SNP genotyping platforms. Hum Mutat 29: 1452-1458.
27. Devlin B, Roeder K, Wasserman L, (2000) Genomic control for association studies: a semiparametric test to detect excess-haplotype sharing. Biostatistics 1: 369-387.
28. Devlin B, Roeder K, Wasserman L, (2001) Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 60: 155-166.
29. Devlin B, Bacanu SA, Roeder K, (2004) Genomic Control to the extreme. Nat Genet 36: 1129-1130; author reply 1131.
30. Zhao JH, Curtis D, Sham PC, (2000) Model-free analysis and permutation tests for allelic associations. Human Heredity 50: 133-139.
31. Morton LM, Purdue MP, Zheng T, Wang SS, Armstrong B, et al. (2009) Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 18: 1259-1270.
32. Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, et al. (2010) Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 19: 2847-2858.
33. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57: 289-300.
34. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, et al. (2007) Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 81: 405-413.
35. Johansson A, Vavruch-Nilsson V, Cox DR, Frazer KA, Gyllensten U, (2007) Evaluation of the SNP tagging approach in an independent population sample-array-based SNP discovery in Sami. Hum Genet 122: 141-150.
36. de Bakker PI, Burtt NP, Graham RR, Guiducci C, Yelensky R, et al. (2006) Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 38: 1298-1303.
37. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, et al. (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 103: 7024-7029.
38. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, et al. (2007) Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A 104: 16170-16175.
39. Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, et al. (2008) MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 28: 621-629.
40. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999-3004.
41. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, et al. (2010) Reprogramming of miRNA networks in cancer and leukemia. Genome Res 20: 589-599.
42. Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, et al. (2007) Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 35: 4535-4541.
43. Shen J, Ambrosone CB, Zhao H, (2009) Novel genetic variants in microRNA genes and familial breast cancer. Int J Cancer 124: 1178-1182.
44. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, et al. (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 105: 7269-7274.
45. Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, et al. (2009) microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res 69: 5970-5977.
46. Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, et al. (2010) Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat.
47. Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, et al. (2010) Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat 31: E1052-1057.
48. Eis PS, Tam W, Sun L, Chadburn A, Li Z, et al. (2005) Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 102: 3627-3632.
49. Jung I, Aguiar RC, (2009) MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma. Br J Haematol 144: 138-140.
50. Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR, (2010) Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol 84: 11670-11678.
51. Wang SS, Purdue MP, Cerhan JR, Zheng T, Menashe I, et al. (2009) Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One 4: e5360.
52. Zhang Y, Lan Q, Rothman N, Zhu Y, Zahm SH, et al. (2005) A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. J Natl Cancer Inst 97: 1616-1618.
53. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, et al. (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110.
54. Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, et al. (2008) Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res 68: 10178-10186.
55. Fernberg P, Chang ET, Duvefelt K, Hjalgrim H, Eloranta S, et al. (2010) Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control 21: 759-769.
56. Au WY, Fung A, Liang R, (2005) Molecular epidemiology of follicular lymphoma in Chinese: relationship with bcl-2/IgH translocation and bcl-6 397G/C polymorphism. Ann Hematol 84: 506-509.
57. Susova S, Trneny M, Soucek P, (2006) Single nucleotide polymorphism in 5′-flanking region of BCL6 is not associated with increased risk of non-Hodgkin's lymphoma. Cancer Lett 238: 142-145.
58. Yuille MR, Stone JG, Bradshaw PS, Houlston RS, (1999) Bcl10 in chronic lymphocytic leukaemia and T-cell prolymphocytic leukaemia. Br J Haematol 107: 384-385.
59. Scott K, Adamson PJ, Willett EV, Worrillow LJ, Allan JM, (2008) Genetic variation in genes expressed in the germinal center and risk of B cell lymphoma among Caucasians. Haematologica 93: 1597-1600.
60. Zenz T, Habe S, Benner A, Kienle D, Dohner H, et al. (2008) The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica 93: 1111-1113.
61. Wrench D, Waters R, Carlotti E, Iqbal S, Matthews J, et al. (2009) Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma. Haematologica 94: 148-150.
62. Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT, (2009) TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet 195: 31-36.
63. Berglund M, Amini RM, Book M, Rosenquist R, Roos G, et al. (2006) Subtype preference of the BCL6397G/C polymorphism in germinal-center and non-germinal-center subtypes of diffuse large B-cell lymphoma. Blood 108: 3623-3624.